Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: Characterizing disease severity and assessing responsiveness to clinical change

British Journal of Dermatology

Volumn 173, Issue 4, 2015, Pages 969-974

  Anyanwu, C O ^a,b   Fiorentino, D F ^c   Chung, L ^c   Dzuong, C ^c   Wang, Y ^d   Okawa, J ^b   Carr, K ^b   Propert, K J ^d   Werth, V P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CUTANEOUS DERMATOMYOSITIS DISEASE AREA AND SEVERITY INDEX; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE SEVERITY; DISEASE SEVERITY ASSESSMENT; FEMALE; HUMAN; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SKIN DISEASE ASSESSMENT; TREATMENT RESPONSE; VALIDATION STUDY; VISUAL ANALOG SCALE; MIDDLE AGED; OBSERVER VARIATION; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DERMATOMYOSITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSERVER VARIATION; ROC CURVE; SEVERITY OF ILLNESS INDEX; VISUAL ANALOG SCALE; YOUNG ADULT;

EID: 84946491330     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13915     Document Type: Article

References (15)

1. Rider LG, Werth VP, Huber AM, et al,. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis. Arthritis Care Res 2011; 63: 118-57.
2. Reeder MJ, Wetter DA, Li X, et al,. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010; 146: 26-30.
3. Goreshi R, Chock M, Foering K, et al,. Quality of life in dermatomyositis. J Am Acad Dermatol 2011; 65: 1107-16.
4. Albrecht J, Taylor L, Berlin JA, et al,. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 889-94.
5. Gaines E, Werth BP,. Development of outcome measures for autoimmune dermatoses. Arch Dermatol Res 2008; 300: 3-9.
6. Klein RQ, Bangert CA, Costner M, et al,. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008; 159: 887-94.
7. Singer AJ, Thode HC, Hollander JE,. Research fundamentals: selection and development of clinical outcome measures. Acad Emerg Med 2000; 7: 397-401.
8. Yassaee M, Fiorentino D, Okawa J, et al,. Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument. Br J Dermatol 2010; 162: 669-73.
9. Goreshi R, Okawa J, Rose M, et al,. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dermatol 2012; 132: 1117-24.
10. Corzillius M, Fortin P, Stucki G,. Responsiveness and sensitivity to change of SLE disease activity measures. Lupus 1999; 8: 655-9.
11. Hundley JL, Carroll CL, Lang W, et al,. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol 2006; 54: 217-20.
12. Heald P, Mehlmauer M, Martin AG, et al,. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 2003; 49: 801-15.
13. Farrar JT, Berlin JA, Strom BL,. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage 2003; 25: 406-11.
14. Bonilla-Martinez ZL, Albrecht J, Troxel AB, et al,. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2008; 144: 173-80.
15. Chang YC, Propert KJ, Werth VP,. The limitations in measuring improvement in disease activity in patients with mild cutaneous lupus erythematosus. J Invest Dermatol 2013; 133: S32.